EPIDIOLEX® (cannabidiol)
The first and only FDA approved cannabidiol.
OUR COMPANY
Medical Affairs
Information and resources for healthcare professionals.
MEDICAL INFORMATION
Submit a Medical Inquiry
For questions about scientific and clinical information regarding Greenwich Biosciences products, submit a medical request form or contact Medical Information by phone.
Recent Publications
The links to these reprints are being provided for educational purposes only. The data reported in these publications may differ from or may not be included in the full Prescribing Information. See link to full prescribing information above. Prescription drugs used outside of their approved indications may not be eligible for reimbursement by third-party payers including Medicare, Medicaid or similar federal or state programs. Financial and conflict of interest disclosures are included within each respective publication.
Cannabinoid Educational Resources
For more information about cannabinoids, access the resources at the links below.
Clinical Trials
Access ClinicalTrials.gov for a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. It is a service of the US National Institutes of Health.
Educational Grant Requests
Greenwich Biosciences is now part of Jazz Pharmaceuticals.
For information on Medical Educational Grants click here
Educational Resources
This section contains helpful resources including videos, symposia, and downloadable educational materials about the science behind our mission.
Disease Education Materials
CME/CE
The Pharmacist Role in Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Jacquelyn Bainbridge, PharmD, FCCP
Expires: August 23, 2022
Navigating Cannabidiol Use in Seizure Disorders: A Roadmap for Managed Care and Specialty Pharmacists
Jacquelyn L. Bainbridge, PharmD, FCCP; Sheldon J. Rich, R.Ph., Ph.D.
Expires: November 21, 2020
Real‐World Approaches to Cannabinoids in Pediatric‐Onset Epilepsy: What Do the Data Tell Us?
Anup Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: December 19, 2020
Finessing the Discussion During the Transition of Care in Pediatric Epileptic Encephalopathies
Lawrence W. Brown, MD; Gregory D. Cascino, MD; Christina SanInocencio, MS
Medscape website will ask you to log in, but registration is free.
Expires: February 7, 2021
Getting the Conversation Right in Epilepsy: How to Talk With Your Patients About Cannabinoids
Anup D. Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: May 6, 2021
Cannabidiol (CBD): A Tale of Two Products
C. Michael White, Pharm D
Expires: May 15, 2021
CPNP symposium: Cannabis Confusion: Sorting Out the Differences and Legality of CBD, Marijuana and Hemp Products
Jacquelyn L. Bainbridge, PharmD, FCCP; Laura Borgelt, PharmD, MBA, FCCP, BCPS
Expires: May 20, 2021
Assessing Practice Patterns in the Management of Tuberous Sclerosis Complex
Elizabeth A. Thiele, MD, PhD
Medscape website will ask you to log in, but registration is free.
Expires: May 29, 2021
A Quick Reference Guide to the Therapeutic Use of Cannabinoids in Epilepsy
Orrin Devinsky, MD
Medscape website will ask you to log in, but registration is free.
Expires: June 8, 2021
Test Your Expertise in Rare, Pediatric-Onset Epilepsies: An Online Medical Simulation
Tyler Elyse Gaston, MD; Anup Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: June 11, 2021
Pharmaceutical- vs Dispensary-Sourced Cannabinoids: What's the Difference?
Daniel Friedman, MD, MSc; Anup D. Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: March 21, 2019
The Basis of Cannabinoid Therapeutics: What You Need to Know
Ethan Russo, MD; Barry Gidal, PharmD
Medscape website will ask you to log in, but registration is free.
Expires: October 31, 2019
Cannabinoids In Epilepsy: New Horizons for Improving the Management of Severe Seizure Disorders
Jacquelyn L. Bainbridge, PharmD, FCCP
Expires: December 10, 2019
Straight Talk: The Intersection of Clinical and Patient Perspectives on Cannabinoids for Epilepsy
Tracy A. Glauser, MD; Orrin Devinsky, MD; Tracy Dixon Salazar, PhD; Anup D. Patel, MD; Elizabeth A. Thiele, MD, PhD
Medscape website will ask you to log in, but registration is free.
Expires: December 17, 2019
Expanded Access
Participation in one of our clinical trials is the optimal way for patients to gain access to our investigational medicines. However, we understand that some patients may not be able to participate in a clinical trial and may seek access to investigational medicines before they are approved. For such patients, the FDA may authorize Expanded Access Programs (EAPs), also known as Compassionate Use Programs, to facilitate access to investigational drugs for the treatment of patients with a serious or immediately life-threatening disease or a condition which lacks therapeutic alternatives.
To obtain more information about Expanded Access, click here.
How To Obtain More Information About Expanded Access
General information
- Currently, we are not reviewing new physician applications.
- An EAP may either be a corporate-sponsored program or be led by physicians and/or states.
- Not all investigator or state-led EAPs are listed on the clinicaltrials.gov website.
- Please note, all cannabis-derived investigational therapies not yet approved by FDA are considered Schedule I controlled substances in the US and specific DEA permits are required to prescribe and dispense the product, even in such emergency situations. This is true regardless of individual state law.
Criteria Used For Considering Requests For Expanded Access
Greenwich Biosciences will consider granting expanded access to an investigational product only if all of the following criteria are met:
- The patient has a serious or immediately life-threatening disease or condition.
- The patient is ineligible, or otherwise unable to, participate in a clinical trial.
- There is no comparable or satisfactory alternative therapy for the disease or condition, or such therapies have already been tried without response.
- Sufficient clinical evidence of safety and effectiveness in the indication has been established, the potential benefit justifies the potential risks, and the potential risks are not unreasonable within the context of the disease or condition.
- Product is under active development in the indication and expanded access will not interfere with the development of the product.
- Greenwich Biosciences has adequate supply of investigational product.
- There is a regulatory mechanism in the country or region to support expanded access.
- The program must be discontinued as soon as feasible when approval of the drug is achieved in the country.
- Once a regulatory agency approves a medicine for commercial use, existing expanded access programs will be phased out
In addition to the criteria noted above, Greenwich Biosciences reserves the right to evaluate expanded access requests on additional criteria on a case-by-case basis.